NFL's top doctor defends Philadelphia Eagles handling of Jalen Hurts blood clots but NFLPA has different story

NFL and Players Union at Odds Over Jalen Hurts’ Blood‑Clot Care

In a clash that has rattled the National Football League’s medical oversight, league officials and the NFL Players Association (NFLPA) offered conflicting accounts of how Philadelphia Eagles quarterback Jalen Hurts’ blood‑clot condition was handled. The dispute emerged at the league’s fall meeting on Tuesday, when the NFL announced it was “satisfied” with the Eagles’ approach, while the union released a statement demanding a full investigation.

A League‑Wide Review, or a Quick Decision?

During the fall league meeting, NFL officials said they had examined the medical care that the Eagles provided to Hurts, who was ruled out of Sunday’s game “out of an abundance of caution” after a blood‑clot diagnosis. Dr. Allen Sills, the league’s chief medical officer, defended the Eagles’ medical staff, saying, “I have complete confidence in the Eagles medical staff and their handling of this situation and what characterize their work as very conservative, very patient‑focused and appropriately guarded at every step.” He noted that in a typical season only a handful of players suffer deep vein thrombosis and that each case is reviewed. “Everyone was incredibly conservative and incredibly vigilant and was very quick to make diagnoses of these conditions that might not have been diagnosed in a non‑athlete,” he added.

Sills also highlighted that the team used “state‑of‑the‑art imaging that was done in London” and that the league’s committee reviews such cases jointly with the Players Association to learn from them.

NFL executive vice‑president of communications, public affairs and policy Jeff Miller told reporters that the league had spoken to the Eagles’ staff, the independent hospital, and the doctors involved. “We have a complete understanding of the course of events,” he said, implying that no formal investigation was required.

The Players Union’s Push for a Review

In response, the NFLPA released a statement on Tuesday evening that contradicted the league’s assurances. “The NFLPA is not aware of any NFL investigation into the medical care provided to Jalen Hurts,” the union said. “In fact, the league previously informed the union that it did not plan to review the care he received.”

The statement went on to say, “Before conclusions are drawn about how this situation was handled, there must be a full investigation into what occurred.” The union’s position underscores a broader concern among players that the league may be “drawing conclusions” without a thorough inquiry.

The NFLPA’s stance came after the league had already called reports about the incident “considerable and uninformed speculation.” The union’s call for a review reflects its broader role in ensuring player health and safety protections.

The Bigger Picture: Player Health and Safety

Hurts’ blood‑clot scare is the latest in a series of medical incidents that have prompted scrutiny of NFL medical protocols. While the league maintains that it reviews every case, the NFLPA’s demand for a formal investigation signals lingering doubts about the thoroughness of that review process.

The disagreement also touches on the league’s relationship with independent medical experts. Dr. Sills highlighted that the imaging used to diagnose Hurts’ clot was performed in London, suggesting an outside evaluation. Yet the NFLPA questions whether the league’s confidence in the Eagles’ handling truly reflects an objective, independent assessment.

Looking Forward

The dispute over Hurts’ care illustrates a tension between the NFL’s desire to protect its public image and the players’ need for transparency and accountability. As the league and union continue to exchange statements, the outcome may set a precedent for how future medical cases will be handled, and whether the NFL will be compelled to formalize its internal review processes.

For now, Hurts remains on the sidelines, and the question of whether the Eagles and the NFL conducted a thorough, independent review of his care remains unresolved. The NFLPA’s insistence on a full investigation may ultimately shape the next steps in the league’s approach to player health and safety.